EAN News

David B. Vodušek (DV): Can you kindly illustrate how the idea of creating NBCs came about and what their intrinsic value is to EBC? F. Destrebecq (FD): The EBC has been founded to catch the ear of the EU decision makers. However, soon it became clear that by focusing only on Brussels, the EBC would not be able to achieve its full potential of influence.

As in the previous year, EANpages asked EAN committee members, panel chairs, and invited speakers  which session one should not miss at the upcoming congress in Amsterdam 2017. Please find their answers below!

Abstract Submission Deadline is January 13, 2017!  In order to submit an abstract, please log in/register on www.ean.org/amsterdam2017 and go to your MyEAN area. There you can update your personal data and also find a link to the abstract submission… Continue Reading

European institutions are sometimes discredited and put into questions. This is particularly true in these times of populistic political movements which try to steer the wheel of European unification backwards. Reasons given by opponents are that ‘European efforts are considered too slow, too burocratic and too inflexible’. ‘There are too many cooks preparing the meal’. Sometimes we hear this also from scientists. The logical conclusion is to spend the money at home in their own countries. The latter view is sometimes even expressed by people who in principle share the European perspective. Populistic politicians go so far to even question the whole EU project. In this respect medical research community can make an argument and a big contribution to the understanding why the EU is important.

…and register to the EAN congress in Amsterdam 2017. It is not only that you can save more than 100€ if you register now, but you will be able to cover the big five neurological diseases, as well as rare… Continue Reading

EAN pages strives to present one country every month to the readers of the EAN pages. We have seen presentations from Albania, Croatia, Denmark, Estonia, Finland, Georgia, and Ireland so far and I would draw your attention to these wonderful articles in our newsblog. This month we have Latvia and in December it will be Moldovia. The country where the EAN congresses take place (so far Germany and Denmark) are even presented in a series of articles covering special aspects of the development of local neurology. The top neurologists from these countries take their time to present important aspects of their country like Denmark did before the Copenhagen congress in 2016. In a series of seven articles they have presented the state of the art and research in their country concerning basic MS research, pain, dementia, clinical MS research, cerebral blood flow research, clinical neurophysiology and headache. The care structures for patients and how research is helping to develop new treatments and new innovations are outlined and one can learn from their success. Whenever I read their presentations it reminds me to the rich history of neurology in Europe. All the different countries were able to show their particular contribution to the field and the achievements they have reached to provide better patient care.

David B. Vodušek (DV): As a senior experienced European neurologist, can you illustrate the role you give to EAN within the community of European Neurologists? Claudia Sommer (CS): The EAN is the umbrella society for the community of European Neurologists, and I am more than glad that after many years, we have achieved to build one strong society.

It is a dream of neurologists to cure degenerative diseases. The big brothers, Alzheimer’s and Parkinson’s disease have always been a huge burden of the population but are now, in the millennium of increasing population age becoming a scourge of humanity. While everybody is acknowledging this, both PD (1) and AD (2) communities of clinician researchers and basic researchers are preparing to attack the problem fundamentally frequently unnoticed by the general neurology community.

It is a dream of neurologists to cure degenerative diseases. The big brothers, Alzheimers’ and Parkinsons’ disease have always been a huge burden of the population but are now, in the millennium of increasing population age becoming a scourge of humanity. While everybody is acknowledging this, both PD1 and AD2 communities of clinician researchers and basic researchers are preparing to attack the problem fundamentally frequently unnoticed by the general neurology community.